Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super...

Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip;
Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip
Supports Efficacy of Low Dose Tobacco Product

WASHINGTON, May 20 /PRNewswire-USNewswire/ -- Fuisz Tobacco today announces
the results of a cross-over clinical study comparing the absorption of
nicotine from the use of Fuisz Tobacco's dissolving tobacco strip and the use
of a nicotine 2mg chewing gum -- the study's control.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080115/CLTU066 )

The results demonstrate extraordinary nicotine bioavailability for the Fuisz
Tobacco strip. A Fuisz Tobacco strip containing 75 mg's of tobacco delivered
substantially higher peak nicotine plasma concentration than the 2 mg nicotine
chewing gum control product. This suggests that the Fuisz Tobacco strip
delivers nicotine more than five times more effectively than the SNUS tobacco
format, which is considered to represent the most efficacious smokeless
tobacco format for nicotine delivery currently available.

The study design was based upon the Lunell study of Swedish SNUS nicotine
absorption. The Lunell study is part of the so called Gothiatek(R) standards
developed by leading SNUS marketer Swedish Match.

Joseph Fuisz, Fuisz Tobacco's Managing Member commented: "These study results
represent a remarkable advance for smokeless tobacco. By delivering tobacco
satisfaction from a dramatically smaller amount of tobacco, we can
substantially lower the amount of tobacco used in the adult consumer friendly
Fuisz Tobacco strip. This news should be welcomed by the harm reduction
community, the tobacco industry, and adult smokers alike."

Fuisz Tobacco's Founding Member, Richard Fuisz, M.D., stated: "We have a new
concept here. The Fuisz Tobacco strip is not a cigarette and yet the user gets
nicotine from its tobacco. This is not a pouch that does not efficiently
transfer nicotine and then must be removed from the mouth and is
environmentally as damaging as a cigarette. This gives off no smoke and is
unaffected by smoking bans. This is not an ill tasting lozenge. This is in
fact the new way for adult tobacco users to gain satisfaction in a simple
straightforward manner. Easier to use than SNUS, a small strip is simply
placed in the cheek and allowed to dissolve."

Joseph Fuisz, continued: "It is important to understand that the Fuisz Tobacco
strip's super bioavailability is used to lower the amount of tobacco contained
in our smokeless product, and not to develop ever-higher nicotine plasma
concentrations. The Fuisz tobacco strip offers not only excellent tobacco
satisfaction but is a great tasting product that appeals greatly to the vast
majority of adult smokers, most of whom are not inclined to use existing
smokeless tobacco products."

The clinical study was performed by an independent contract research
organization that serves the pharmaceutical industry.

The Fuisz Tobacco smokeless tobacco product is a tobacco containing sheet,
similar in appearance to a Listerine(R) PocketPak(R) breath strip but
substantially thicker and taking longer to dissolve. The Fuisz Tobacco strip
is spitless and dissolves entirely in the cheek. This means that the product
can be discretely consumed in a social setting without residue to remove from
the mouth after use -- unlike traditional smokeless tobacco products. Fuisz
Tobacco's tobacco strip technology is protected by multiple patents pending
and licenses.

Fuisz Tobacco is a private company. Its founding partner, Richard C. Fuisz,
M.D., is a noted pharmaceutical inventor, including in the thin film drug
delivery, quick dissolve tablet, taste masking and controlled release fields
(http://www.en.wikipedia.org/wiki/Richard_Fuisz). Fuisz Tobacco's managing
partner, Joseph Fuisz, is a corporate lawyer and is a named inventor on over
forty thin film drug delivery patents issued and pending. Mr. Fuisz
previously served as Senior Vice President for Business Development of MonoSol
Rx (www.monosolrx.com). He is a graduate of Yale College and the Columbia Law
School.

SOURCE Fuisz Tobacco

Joseph Fuisz of Fuisz Tobacco, +1-202-669-5097, jfuisz@fuisz.com